Literature DB >> 10387073

Divalent cations stabilize the alpha 1 beta 1 integrin I domain.

P J Gotwals1, G Chi-Rosso, S T Ryan, I Sizing, M Zafari, C Benjamin, J Singh, S Y Venyaminov, R B Pepinsky, V Koteliansky.   

Abstract

Recent structural and functional analyses of alpha integrin subunit I domains implicate a region in cation and ligand binding referred to as the metal ion-dependent adhesion site (MIDAS). Although the molecular interactions between Mn2+ and Mg2+ and the MIDAS region have been defined by crystallographic analyses, the role of cation in I domain function is not well understood. Recombinant alpha 1 beta 1 integrin I domain (alpha1-I domain) binds collagen in a cation-dependent manner. We have generated and characterized a panel of antibodies directed against the alpha1-I domain, and selected one (AJH10) that blocks alpha 1 beta 1 integrin function for further study. The epitope of AJH10 was localized within the loop between the alpha 3 and alpha 4 helices which contributes one of the metal coordination sites of the MIDAS structure. Kinetic analyses of antibody binding to the I domain demonstrate that divalent cation is required to stabilize the epitope. Denaturation experiments demonstrate that cation has a dramatic effect on the stabilization of the I domain structure. Mn2+ shifts the point at which the I domain denatures from 3.4 to 6.3 M urea in the presence of the denaturant, and from 49.5 to 58.6 degrees C following thermal denaturation. The structural stability provided to the alpha1-I domain by divalent cations may contribute to augmented ligand binding that occurs in the presence of these cations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10387073     DOI: 10.1021/bi982860m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  The alpha2beta1 integrin inhibitor rhodocetin binds to the A-domain of the integrin alpha2 subunit proximal to the collagen-binding site.

Authors:  Johannes A Eble; Danny S Tuckwell
Journal:  Biochem J       Date:  2003-11-15       Impact factor: 3.857

2.  Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design.

Authors:  Louis A Clark; P Ann Boriack-Sjodin; John Eldredge; Christopher Fitch; Bethany Friedman; Karl J M Hanf; Matthew Jarpe; Stefano F Liparoto; You Li; Alexey Lugovskoy; Stephan Miller; Mia Rushe; Woody Sherman; Kenneth Simon; Herman Van Vlijmen
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

3.  Measurement of cationic and intracellular modulation of integrin binding affinity by AFM-based nanorobot.

Authors:  Kevin C Patterson; Ruiguo Yang; Bixi Zeng; Bo Song; Shouye Wang; Ning Xi; Marc D Basson
Journal:  Biophys J       Date:  2013-07-02       Impact factor: 4.033

4.  Antibodies against thrombospondin-related anonymous protein do not inhibit Plasmodium sporozoite infectivity in vivo.

Authors:  S Gantt; C Persson; K Rose; A J Birkett; R Abagyan; V Nussenzweig
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

5.  Dynamic structural changes are observed upon collagen and metal ion binding to the integrin α1 I domain.

Authors:  Paul H Weinreb; Sheng Li; Sharon X Gao; Tong Liu; R Blake Pepinsky; Justin A Caravella; Jun H Lee; Virgil L Woods
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

6.  Magnesium Activates Microsecond Dynamics to Regulate Integrin-Collagen Recognition.

Authors:  Ana Monica Nunes; Conceição A S A Minetti; David P Remeta; Jean Baum
Journal:  Structure       Date:  2018-06-21       Impact factor: 5.006

Review 7.  Insights into integrin-ligand binding and activation from the first crystal structure.

Authors:  Martin J Humphries
Journal:  Arthritis Res       Date:  2002-05-09

8.  Dual role for pilus in adherence to epithelial cells and biofilm formation in Streptococcus agalactiae.

Authors:  Yoan Konto-Ghiorghi; Emilie Mairey; Adeline Mallet; Guillaume Duménil; Elise Caliot; Patrick Trieu-Cuot; Shaynoor Dramsi
Journal:  PLoS Pathog       Date:  2009-05-08       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.